STOCK TITAN

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals (CTXR) announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two New York City investor conferences in September 2026.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Citius Pharmaceuticals (CTXR) announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two New York City investor conferences in September 2026.

He will discuss the company’s business, recent developments, the ongoing commercialization of LYMPHIR by majority-owned subsidiary Citius Oncology (CTOR), and the progress of its late-stage pipeline. Mazur is scheduled to speak at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9, 2026, from 3:15 pm to 4:00 pm ET at The Westin New York Grand Central, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, from 2:00 pm to 2:30 pm ET at the Lotte New York Palace Hotel. Both appearances are expected to have webcast access via conference-provided links, and presentation times are subject to change based on the final agendas.

Loading...
Loading translation...
Argus Sep 3 session 3 alerts
+1.86% close to close 1.6x rel. volume Open Argus
Details

News Market Reaction – CTOR

+2.7% Peak Tracked
$92.12M Mkt Cap at Peak Alert

On Sep 3, the day this news came out, CTOR closed 1.86% above the previous close. Argus tracked a peak move of +2.7% during that session. Our momentum scanner recorded 3 alerts in the available session data. Relative volume reached 1.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Investor conferences: two conferences H.C. Wainwright conference: 28th Annual Global Investment Conference Moody conference dates: September 9–10, 2026 +2 more
Investor conferences
two conferences
September 2026
H.C. Wainwright conference
28th Annual Global Investment Conference
September 14–16, 2026
Moody conference dates
September 9–10, 2026
Moody Capital Solutions 2026 conference
Moody presentation time
3:15 pm–4:00 pm ET
September 9, 2026
H.C. Wainwright presentation time
2:00 pm–2:30 pm ET
September 15, 2026

Historical Context

4 past events · Latest: Aug 14
4 events
  1. Aug 14

    Q3 earnings

    24h Move
    -15.6%

    Initial LYMPHIR commercialization produced revenue alongside reported quarterly and nine-month net losses.

  2. Aug 12

    Board appointment

    24h Move
    +11.0%

    Independent director appointment expanded the board to nine members, effective August 10.

  3. Aug 05

    Commercial update

    24h Move
    +18.9%

    Commercial momentum included 78% quarterly account growth and 31% higher vial orders.

  4. Jul 21

    Commercial update

    24h Move
    +0.0%

    Commercial organization added 21 field professionals and eight medical science liaisons.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CRANFORD, N.J., Sept. 3, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.

During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company's business and recent developments, including the ongoing commercialization of LYMPHIR® (denileukin diftitox-cxdl) by the Company's majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), and the continued advancement of the Company's late-stage pipeline.

Moody Capital Solutions Conference:

  • Conference: Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
  • Dates: September 9–10, 2026
  • Location: The Westin New York Grand Central, New York, NY
  • Presentation Date & Time: Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET
  • Webcast: webcast link 
     

H.C. Wainwright Conference:

  • Conference: H.C. Wainwright 28th Annual Global Investment Conference
  • Dates: September 14–16, 2026
  • Location: Lotte New York Palace Hotel, New York, NY
  • Presentation Date & Time: Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET
  • Webcast: webcast link

Please note that the presentation dates and times are subject to change. Participants should refer to the final program agenda for up-to-date information.

Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company's investor relations team.

About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

 

Citius Pharmaceuticals, a late-stage biopharmaceutical company

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences-302868503.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Citius Pharmaceuticals (CTXR) participate in during September 2026?

Citius Pharmaceuticals will participate in two New York City investor events in September 2026: the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Chairman and CEO Leonard Mazur will present at both.

When is Citius Pharmaceuticals’ presentation at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference?

Citius Pharmaceuticals is scheduled to present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on Wednesday, September 9, 2026, from 3:15 pm to 4:00 pm ET at The Westin New York Grand Central in New York, NY.

When will Citius Pharmaceuticals (CTXR) present at the H.C. Wainwright 28th Annual Global Investment Conference?

At the H.C. Wainwright 28th Annual Global Investment Conference, Citius Pharmaceuticals is scheduled to present on Tuesday, September 15, 2026, from 2:00 pm to 2:30 pm ET at the Lotte New York Palace Hotel in New York, NY.

What topics will Citius Pharmaceuticals’ CEO cover at the September 2026 investor conferences?

Leonard Mazur plans to provide an overview of Citius Pharmaceuticals’ business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by majority-owned subsidiary Citius Oncology (CTOR) and the continued advancement of the company’s late-stage pipeline.

Will Citius Pharmaceuticals’ September 2026 conference presentations be available via webcast?

Both the Moody Capital Solutions and H.C. Wainwright presentations are expected to have webcast access through their respective webcast links. The company advises participants to check the final conference program agenda for the latest webcast details and any schedule changes.

How can investors schedule one-on-one meetings with Citius Pharmaceuticals’ management at the September 2026 conferences?

Investors interested in one-on-one meetings with Citius Pharmaceuticals’ management are advised to contact either their conference representative or the company’s investor relations team to arrange a meeting during the conferences.

Are the Citius Pharmaceuticals (CTXR) conference presentation times in September 2026 final?

The company notes that presentation dates and times are subject to change. Participants should refer to the conferences’ final program agendas for the most up-to-date scheduling information before attending or joining the webcasts.

Keep reading